Snowden Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

Snowden Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	–	–	1695
2021 Q4	$0	Buy	+4	New	+$868	﹤0.01%	2101

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Snowden Capital Advisors's NKTR Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 4 shares.

Snowden Capital Advisors first reported a position in NKTR in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 239 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

Snowden Capital Advisors reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 4 Nektar Therapeutics shares in Q1 2022.
Snowden Capital Advisors first reported a position in Nektar Therapeutics in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Nektar Therapeutics position peaked at $0 in Q4 2021.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.